targeting vector (Figure 1a) , which was transfected into J1 embryonic stem (ES) cells. Chimeric mice, generated by injecting targeted ES cells into C57BL/6J blastocysts (16) , were mated to C57BL/6J female mice to obtain germline transmissions of the mutation. Southern blotting was performed to genotype the progeny by using the genomic DNA fragment shown in Figure 1a as a probe (Figure 1b) . The tail DNA was digested with BamHI. Western blot analysis, using purified-monoclonal anti-α 1D antibody, confirmed the absence of α 1D proteins. Cerebral membrane proteins (30 µg) were separated on an 8-16% gradient SDS-PAGE gel (Invitrogen Corp., San Diego, California, USA). The mAb (α 1D 185-1) was raised against the α 1D peptide (RNKNSDKQR-SA, corresponding to residues 2048-2058 of human α 1D ) and purified as described previously (17) .
Animals. The mice used had mixed genetic backgrounds of 129/svJae and C57BL/6J. Age-and sex-matched littermate animals were used as controls in all experiments. Animals were subjected to a 12-hour light/dark cycle, with free access to food and water. Animal care and handling was carried out according to the guidelines of the Pohang University of Science and Technology.
Blood glucose and insulin measurement. Intraperitoneal glucose tolerance tests were performed by injecting glucose (2 mg per g body weight), following an 18-hour overnight fast. Glucose levels in blood taken from the tails were determined using a One Touch Basic glucometer (Lifescan Canada Ltd., Burnaby, Canada). Blood was taken from the orbital sinus to measure serum insulin concentrations. Insulin tolerance tests were performed on randomly fed animals. Animals were injected with 0.75 IU/kg body weight human insulin (Humulin regular; Eli Lilly and Co., Indianapolis, Indiana, USA) into the peritoneal cavity. Blood glucose levels were measured immediately before and 15, 30, 45 , and 60 minutes after the injection. Pancreatic insulin was extracted with acid ethanol for measuring extractable insulin. Insulin levels were determined using a rat insulin RIA kit (Linco Research Inc., St. Charles, Missouri, USA), with rat insulin as a standard.
Immunohistochemistry. Pancreas was carefully obtained from wild-type and α 1D -/-mice. After weighing, pancreas was immediately fixed with 10% neutral buffered formalin, dehydrated in ethanol, and embedded in paraffin wax. Sections of paraffin-embedded pancreas of 5 µm thickness were incubated overnight with mouse anti-α 1D mAb (185-1; 1:200 dilution), anti-α 1C antibody (1:70 dilution; Alomone Labs, Jerusalem, Israel), guinea pig anti porcine-insulin (DAKO Corp., Glostrup, Denmark), glucagon (DAKO Corp.), pancreatic polypeptide (Zymed Inc., Camarillo, California, USA), or somatostatin (Zymed Inc.). They were further incubated with peroxidase-conjugated streptavidin complex (DAKO Corp.) for 30 minutes, followed by 3-ethyl carbazole (AEC) as a substrate chromogen (DAKO Corp.). Because the immunoreactivity of α 1C was too weak in wild-type pancreas, we used a signal amplification kit (CSA; DAKO Corp.) for α 1C staining in both wild-type and α 1D -/-pancreas. Electrophysiology. Pancreatic islets were isolated from 6-to 10-week-old mice by collagenase digestion, as described previously (18) . For the patch clamp experiments, islets were dissociated in trypsin/EDTA (0.05% trypsin, 0.53% EDTA) for 5 minutes at 37°C. Dispersed islets were plated onto cover glasses and cultured for 2-4 days in RPMI 1640 supplemented with 10% FBS and penicillin-streptomycin. More than 80% of dispersed islet cells were insulin-positive β cells, as confirmed by immunocytochemistry, and they were usually bigger than insulin-negative cells. Consequently, only bigger cells were used for measuring the I Ba . Whole-cell recordings were carried out as described previously (15), using 1-4 MΩ electrodes on islet cells. Series resistance ranged from 2 MΩ to 8 MΩ, and was compensated by 75-80%. Recordings were obtained with an Axopatch 200B amplifier (Axon Instruments Inc., Foster City, California, USA). The pClamp6 software (Axon Instruments, Inc.) was used to control all data acquisition and analysis. Currents were filtered 5 kHz, digitized at 100 µs per point, and leak-subtracted using a -P/4 procedure. Pipettes were filled with 130 mM CsCl, 4 mM MgCl 2 , 5 mM TEA·Cl, 10 mM HEPES, 10 mM EGTA, 4 mM Na 2 ATP, and 0.3 Na 2 GTP 0.3 (pH 7.2), whereas the external solution comprised 130 mM NaCl, 4.8 mM KCl, 10 mM BaCl 2 , 1.2 mM MgCl 2 , 5 mM TEA·Cl, 10 mM HEPES, 2.8 mM glucose, and 0.001 mM tetrodotoxin (pH 7.2). Nifedipine (Sigma Chemical Co., St. Louis, Missouri, USA) was applied, using gravity from a linear array of glass capillaries.
Insulin secretion from pancreatic islets in vitro. Glucosestimulated insulin secretion was measured by the method described previously (19) . Islets isolated as described above were cultured for 48 hours in RPMI 1640 supplemented with 10% FBS and penicillin-streptomycin in a 60-mm Petri dish. Cultured islets, 100-200 µm in diameter, were selected after inspection under a microscope. Islets were preincubated in 5% CO 2 at 37°C for 1 hour in a 60-mm Petri dish containing HEPESKrebs buffer composed of 118.4 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 2.4 mM CaCl 2 , 1.2 mM MgSO 4 , 20 mM NaHCO 3 , 3 mM glucose, and 10 mM HEPES (pH 7.4) supplemented with 0.2% BSA. After incubation, islets (5-10 per well) were transferred to a 24-well plate containing 0.3 ml buffer with various concentrations of glucose and were incubated under 5% CO 2 at 37°C for 30 minutes. After incubation, the supernatant was assayed for insulin content with an insulin RIA kit (Linco Research, Inc., St. Charles, Missouri, USA). To normalize insulin secretion per islet, insulin concentration was divided by the number of islets per well. Three or four independent experiments were carried out for each glucose concentration.
Measurement of pancreatic islet mass. To measure the number of islets in the whole pancreas, we counted the islets as described previously with some modifications in the method (20) . The entire pancreas was dissected, weighed, and immersed in 10% buffered formalin. Those were embedded in paraffin and cut serially in 20-µm thickness. Every fifth section was stained with toluidine blue to count the islets. Photographs (200× or 400×) of pancreas sections (5 µm) were used to count the cell number per islet area. To avoid a bias, all the islets in each section were examined. Five female wild-type (85-148 islets per pancreas) and five female α 1D -/-mice both at the age of 30 days old (56-84 islets per pancreas) were examined.
TUNEL staining. Apoptotic cells were identified in 5-µm paraffin-embedded sections of pancreas by in situ detection of DNA fragmentation, using the TUNEL method (ApopTag; Intergen Co., Purchase, New York, USA).
BrdU injections and immunohistochemistry. BrdU (Sigma Chemical Co.) was dissolved in 0.1 M phosphate buffer (pH 7.4). Female mice, at 14 and 30 days of age, were injected intraperitoneally with BrdU (50 mg per kg body weight) and sacrificed after 2 hours. Pancreas was dissected, weighed, and fixed with 10% formaldehyde. All staining was done on 5-µm paraffin-embedded sections of pancreas, pretreated with 3 N HCl for 30 minutes at 37°C to denature DNA. A mouse monoclonal anti-BrdU antibody (1:50; DAKO Corp.) was used. Immunoreactivities were visualized with biotin-streptavidin (LSAB kit; DAKO Corp.), using 3-ethyl carbazole (AEC) as a substrate chromogen. Double immunostaining for BrdU and insulin was performed, as described below. After staining for BrdU (see above), sections were blocked and incubated with guinea pig polyclonal anti-insulin antibody (1:100; DAKO Corp.). After overnight incubation at 4°C, sections were peroxidase labeled with Novostatin Super ABC kit, (Novocastra Laboratories Ltd., Newcastle, UK.) developed with DAB, and counterstained with hematoxylin. Cytosols of β cells stained dark violet, and BrdU-positive cells appeared with red nuclei. β Cells and BrdU-positive β cells were counted using an Olympus BX50 light microscope (Olympus Optical Co. Ltd., Tokyo, Japan) microscope and photographs (200× or 400×). A large number (2,000-5,000) of β cells were examined per animal.
Data analysis. A two-tailed, unpaired, Student's t test was used for statistical analysis. All values are expressed as mean ± SE.
Results α 1D -/-mice are deaf and smaller than their littermates. The α 1D
+/-heterozygotes showed no apparent abnormality and were fertile. Homozygotes (α 1D -/-) were obtained by mating heterozygotes (Figure 1b ). Western blotting of -/-mice (n = 7); filled circles, control littermates (n = 11). *P < 0.05; **P < 0.01. cerebral membrane proteins ( Figure 1c ) and immunostaining of pancreas sections (see Figure 3b ) confirmed the lack of α 1D protein in knockout mice. Homozygous α 1D -/-mice appeared healthy, but smaller (80% of normal body weight) than the littermate controls. The lack of motor reflex in α 1D -/-mice in response to an auditory stimulus (Preyer reflex) and the significantly elevated auditory brainstem response (ABR) threshold for a broadband click (data not shown) confirmed that α 1D -/-mice were deaf, consistent with the phenotype of α 1D knockout mice reported by Platzer et al. (13) .
α 1D -/-mice are hypoinsulinemic and glucose intolerant. Given that α 1D is the dominant L-type channel protein in pancreatic β cells (11, 14) , and inhibitors of L-type channels block most of the glucose-stimulated and depolarization-evoked insulin release (7), we investigated blood glucose homeostasis in the mutants. In nonfasting states, the serum insulin levels in adult α 1D -/-mice were lower than those observed in littermate control mice (Figure 2a) , although blood glucose levels did not differ significantly between the wild-type and mutant mice (154.1 ± 8.9 mg/dl, n = 7 males, wildtype; 159.1 ± 17.7 mg/dl, n = 8 males, α 1D -/-, P = 0.81). Glucose tolerance tests were performed to verify the pancreatic dysfunction in α 1D -/-mice. As shown in Figure 2b , at 12-14 weeks of age, α 1D -/-mice remained hyperglycemic 2 hours after intraperitoneal injection of glucose, whereas in the wild-type mice, blood glucose levels returned to the baseline. The level of serum insulin increased twofold in wild-type mice 30 minutes after glucose injection (after overnight fasting, i.e., before glucose injection, 0.24 ± 0.06 ng/ml, n = 6; 30 minutes after glucose injection, 0.49 ± 0.07 ng/ml, n = 6). We could not quantify the serum insulin in mutant mice, because for the majority of the mutants, the serum insulin levels after overnight fasting were less than 0.1 ng/ml (n = 7), which was the lowest limit of the insulin measuring kit used. Serum insulin levels in α 1D -/-mice, measured 30 minutes after glucose injection, were still below 0.1 ng/ml (n = 5). These data suggest that glucose intolerance in the α 1D -/-mice might be caused by the insulin deficiency. However, α 1D -/-mice exhibited normoglycemia in fed states compared with age-matched littermates and did not develop diabetes over the 1-year observation period. Because enhanced insulin sensitivity might account for these results in α 1D -/-mice, we injected insulin and examined changes in blood glucose levels. Indeed, the glucoselowering effect of insulin was significantly enhanced in α 1D -/-mice, compared with wild-type mice (Figure 3c ).
Compensatory overexpression of α 1C in α 1D
-/-pancreatic β cells. Given that calcium entry through L-type calcium channels is crucial for insulin secretion in β cells (7), we examined the effects of the loss of the α 1D channel on calcium currents and insulin secretion in response to glucose stimulation in α 1D -/-pancreatic β cells. Ca 2+ currents, supported by 10 mM Ba 2+ as a charge carrier, were activated by step depolarizations from a holding potential of -80 mV. Unexpectedly, mutant cells did not show a decrease in either total current density (Figure 3a) or
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The L-type current density, as confirmed by current analyses in the presence of 10 µM nifedipine (Figure 3a) . These results suggest the possibility of a compensatory increase in the other L-type channel, namely α 1C . Immunostaining with anti-α 1C antibody confirmed that α 1C was indeed overexpressed in mutant pancreatic islets, compared with wild-type mice (Figure 3b ). Significantly, a closer examination of electrophysiological data revealed that a current-voltage plot of the mutant cells was shifted by about 10 mV toward more positive potentials at the lower voltage range (Figure 3d) . Therefore, the current density at -10 mV and -20 mV were reduced by approximately 50% and approximately 70% in mutant β cells, respectively (Figure 3d) . However, at potentials of 10 mV or above, the curves looked virtually identical between mutant and wild-type. These results effectively demonstrate the loss of α 1D channels and subsequent compensation by α 1C in the mutant, as α 1D channels have a lower activation threshold than α 1C (10, 13) . Because β cell action potentials in response to glucose stimulation rarely exceed -10 mV (21, 22) , the decreased channel activity below the membrane potential of -10 mV in mutant β cells may affect the secretion of insulin. To examine the consequences of the altered channel profile on the insulin secretory function of islet β cells, we measured insulin secretion from isolated islets in culture in response to ambient glucose, using the batch incubation method. Mutant islets secreted less insulin than control islets at 3 mM ambient glucose (0.019 ± 0.003 ng/30min/islet for control; 0.011 ± 0.002 ng/30min/islet for mutant; P = 0.03), although no statistically significant difference was observed at glucose concentrations of 6 mM or higher (Figure 3e ). These results suggest that the glucose-sensing and subsequent insulin secretion machinery might be largely preserved in isolated α 1D -deficient β cells.
Reduction of β cell mass in α 1D -/-pancreas. Another possible mechanism underlying the hypoinsulinemia and glucose intolerance in α 1D -/-mice could be a reduction of -/-(n = 2 mice for P14 and n = 5 mice for P30). *P = 0.05; **P < 0.005. total β cell mass. We examined islet morphology in the mutant pancreas. Pancreatic islets of α 1D -/-mice were well organized with the insulin-producing β cells forming a central core surrounded by a discontinuous mantle of non β cells (Figure 4a) . A simple scanning of the histological slides under a microscope, however, revealed a marked decrease in islet numbers and a scarcity of larger islets in the mutant pancreas, compared with control (Figure 4a) . At the day of birth (P0), mutant mice showed smaller body weight and a slightly smaller number of islets (Figure 4b) , although the relative islet number (normalized as their body weight) was equivalent to that in littermate wild-type mice (88.1 ± 3.9 per body weight in wild-type mice, and 81.8 ± 3.1 per body weight in α 1D -/-mice at birth [n = 4]; P = 0.24). However, at postnatal day 14 (P14), the islet number was approximately 60% less than that of wild-type littermates, and by P30, we observed approximately 40% fewer islets than in wild-type littermates (Figure 4b ). The relative islet number was also significantly reduced in α 1D -/-pancreas by approximately 40% at P14 (n = 4, P < 0.05) and approximately 30% at P30 (n = 5, P < 0.05). But the pancreas weight (measured as percent body weight) did not differ between the α 1D -/-mice and littermate controls (0.25 ± 0.01% for wild-type mice versus 0.28 ± 0.01% for α 1D -/-mice at P14, P = 0.15; 1.15 ± 0.05% versus 1.25 ± 0.03% at P30, P = 0.15d). Distribution of islet size (shown in Figure 4 by cell numbers in the cross-section), represented as a percentage of islets measured, revealed a significant reduction in the number of larger islets in the mutant pancreas (Figure 4c ). The proportion of β cells in individual islets was significantly reduced, from approximately 72% in wild-type islets to approximately 48% in mutant islets (Figure 4d) . Moreover, the percentage of α cells was relatively increased in mutant islets (data not shown), indicating that reduction of islet mass was mostly caused by a decrease in β cell mass. Somatostatin-and pancreatic polypeptide-positive cells were well preserved in the mutant islets (data not shown). Our data collectively demonstrate that postnatal β cell expansion is impaired in α 1D -/-mice. The reduction in β cell mass may, in turn, lead to hypoinsulinemia and glucose intolerance in α 1D -/-mice. Decreased β cell proliferation in the α 1D -/-mice. To determine whether the decrease in β cell mass was due to a defect in β cell genesis or in survival, we first examined the degree of cell death in islets at P14 and P30, using the TUNEL assay. Previously, it was reported that the frequency of apoptotic β cells is higher throughout the neonatal period than in the adult rat, peaking at 13-17 days after birth (23) . We found no increase in the cell death in mutant islets either at P14 or P30. At P14, the percentage of apoptotic cells was 5.73 ± 0.01% in wildtype islets (n = 2 mice) and 5.42 ± 0.17% in mutant islets (n = 2 mice). At P30, there were only six apoptotic cells over 49 islets in the wild-type and four cells over 41 islets in the mutant pancreas, respectively. This indicates that the decrease in β cell mass in the mutant was not due to an increase in cell death but rather due to a decrease in the proliferation and/or differentiation of β cells. Pancreatic β cell growth can be mediated by neogenesis or differentiation from ductal precursor cells, and replication of differentiated β cells (24, 25) . β Cell neogenesis and replication normally proceeds in mice up to around 3 weeks of age (26, 27) . After weaning, a low level of replication is maintained (24) . As shown in Figure 4b , during the first 2 weeks after birth, increase in islet number was severely impaired in the mutant pancreas. We examined β cell proliferation at P14, by incorporation and immunohistochemical detection of bromodeoxyuridine (BrdU) in the DNA of dividing cells. After 2-hour BrdU labeling, the number of BrdU and insulin double-positive cells per total insulin-positive cells significantly decreased in mutant islets to 53% of that in wild-type at P14, and the difference persisted at P30 (Figure 5b ). In conclusion, the β cell proliferation rate is decreased in the mutant islets, and this may partly contribute to the decrease in β cell mass in α 1D -/-mice.
Discussion
In the present study, we show a marked reduction in total islet mass in α 1D -/-mice, due to impairment of postnatal β cell generation. The actual β cell mass in α 1D -/-mice at P30 is approximately 24-30% of that of wild-type mice, as the total islet number in mutant is approximately 60% of that in wild-type (Figure 4b) , and the number of β cells in individual islets is approximately 40-50% of that in wild-type (Figure 4d) .
We observed an overexpression of α 1C in islets of α 1D -/-mice both in adult (Figure 3b ) and at P14 (data not shown). The maximal current density was restored in the mutant β cells, although the calcium current density at -10 mV to -30 mV was reduced by 50-70% in mutant β cells (Figure 3d ). In spite of the compensatory overexpression of α 1C in mutant β cells and the normal maximal current density, proliferation rate was reduced. These results may suggest two possible roles of α 1D in β cell proliferation. First, calcium entry through α 1D channels at the membrane potentials of below -10 mV may play a role in β cell proliferation. Second, α 1D protein itself may function as one of the components in the mitogenic signaling pathway. These two possibilities do not necessary exclude each other. For the first time, to our knowledge, this study demonstrates that the L-type channel α 1D is one of the major requirements for proper β cell generation. In addition, these results clearly demonstrate distinct functions of the L-type channel isotypes in the pancreas.
The β cell mass reduction in α 1D -/-mice is an unexpected and novel finding, as there have been no reports to show that L-type channels contribute to postnatal β cell generation. With hindsight, however, earlier observations are consistent with the possible involvement of L-type channels in the production of β cells. In pancreatic β cells, glucose uptake leads to an increase in intracellular ATP/ADP ratio and a closure of K ATP channels. This results in membrane depolarization, opening of VDCC, calcium influx, and finally activation of the insulin secretory machinery. It is known that glucose itself induces β cell mitosis in vivo or in vitro (28) . Glibenclamide, a hypoglycemic drug that inhibits K ATP channels, affects the replication rate and mass of β cells in young mice (29) . Moreover, glucagonlike peptide-1 (GLP-1), a regulator of postnatal β cell growth and differentiation, increases levels of β cell cAMP and glucose-stimulated Ca 2+ influx (30) . Recent studies have shown that islet size and function may be determined by the extent of activin receptor-mediated TGF-β signaling (31) . Pancreatic expression of a dominant negative type II activin receptor (dn-ActR) in transgenic mice results in islet hypoplasia (32, 33) , and ActRIIA +/-B +/-mice show hypoplastic pancreatic islets, hypoinsulinemia, and impaired glucose tolerance (34) . Interestingly, activin causes Ca 2+ influx through membrane depolarization by inhibiting the activity of the K ATP channel and directly modulates VDCCs in β cells (35) . However, until now, there have been no reports that L-type channels are involved in the β cell growthpromoting activity of GLP-1 and activin.
Recent studies have demonstrated that a number of transcription factors are necessary in the proper development of the pancreas (31) . Genetic studies have outlined the hierarchy of transcription factors involved in β cell development. For example, the homeodomain factor, IPF1/PDX1, has been proposed to regulate the expression of a variety of different pancreatic endocrine genes including insulin, somatostatin, glucokinase, and glucose transporter 2 (Glut2). Recently, Hart et al. reported that attenuation of FGF signaling in mouse β cells leads to impairment of postnatal β cell expansion (36) and the expression of glucose transporter 2 (Glut2) in these mice. Moreover, the expression of FGF receptors was impaired in IPF1/PDX1 inactivated β cells, and it was claimed that the IPF1/PDX1 acts upstream of FGF receptor (FGFR) signaling. It would therefore be worthwhile to examine the levels of α 1D gene expression in these mice and the transcriptional regulation of α 1D gene in β cell development.
Contrary to our results, Platzer et al. (13) reported recently that α 1D -deficient mice showed no growth retardation or glucose intolerance. There are a number of possible explanations for this discrepancy. First, the difference in the genetic background of the embryonic stem (ES) cell line used for generating knockout mouse might have caused different phenotypes: AB2.2 originating from the 129/SvEv substrain was used in their work, whereas J1 originating from the 129/SvJae substrain was used in our work (37) . The genetic heterogeneity among 129 substrains is well documented (37, 38) . The phenotypes resulting from the disruption of genes in insulin production and insulin signaling pathways are critically dependent on the genetic background of the mouse used (39) (40) (41) . Second, we used a different targeting strategy to the other group. For example, we deleted the locus spanning the 3′ end of the first exon to the 5′ part of the second exon that included an intron in between, whereas they inserted neocassette into the second exon. Further molecular analysis of each mutant with regard to the status of the α 1D locus, such as aberrantly spliced products, may provide an answer.
Despite the reduction of β cell proportion in individual α 1D
-/-islets ( Figure 4d ) and the decrease in Ca 2+ channel activity at the lower range of membrane potentials in mutant β cells (Figure 3d) , there is no decrease in insulin secretion in response to glucose stimulation except at the basal glucose concentration in α 1D -/-islets (Figure 3e ). This discrepancy implies that insulin secretion per β cell may be enhanced in mutant islets. In fact, analysis of insulin content in individual islets revealed that mutant islets contained more insulin than did similar size of wild-type islets (41.0 ± 2.4 ng/islet in mutant islets, n = 63 islets from three mice; 27.8 ± 2.2 ng/islet in wild-type islets, n = 66 islets from three wild type mice, P < 0.001). Considering the decreased proportion of β cells in mutant islets (Figure  4d ), insulin content per β cell increased twice in mutant islets. However, it is unlikely that there is an increase in individual β cell volume (hypertrophy) in α 1D -/-islets, because no significant difference was observed in cell capacitance (pF) between wild-type and α 1D -/-cells (Figure 3b , legend). This increase in insulin content per islet accounts for the increase in insulin secretion from mutant islets. The average total insulin content in the pancreas (µg/g pancreas) in 6-to 7-weekold α 1D -/-mice was approximately 39% that of control mice, which indicates that total β cell number might be approximately 20%, compared with wild-type mice.
It will be interesting to see whether there is any difference in the change of membrane potential in response to glucose between the wild-type and the mutant β cells. Glucose-induced membrane depolarization is the intervening step from glucose-sensing to insulin secretion (42) . In addition, inward Ca 2+ currents through VDCCs participate in the generation of action potentials in β cells (42) . There is, however, a great deal of heterogeneity among β cells (22, 43) , and the electrical activity of β cells induced by glucose is dependent on the cell configuration, such as in single cell, a cluster, or an intact islet (21, 22, 43) . Therefore, this issue could be addressed by population studies using perforated patch-clamp recordings of β cells in intact pancreatic islets of wild-type and mutant mice (21) .
The α 1D -deficient mice showed hypoinsulinemia and severely impaired glucose tolerance, which were caused mainly by the reduction of total β cell mass. Increases in insulin content in individual β cells and enhanced insulin sensitivity of peripheral tissues may offer explanations for the lack of overt diabetes in α 1D -/-mice. Similar phenotypes such as impaired glucose tolerance and enhanced insulin sensitivity are observed in the offspring of insulin-sensitive type 2 diabetes patients (44, 45) .
Human type 2 diabetes is strongly associated with genetic and familial backgrounds (46, 47) . Although insulin resistance is an important pathological sign in the early stages of type 2 diabetes, a failure in adequate β cell mass increase leads to progression to a diabetic state (48) . For example, humans with type 2 diabetes have reduced β cell mass, compared with weightmatched nondiabetic subjects (48) . Although mice lacking α 1D did not develop overt diabetes in the 12-month observation period, they might be more prone to diabetogenic conditions such as high-fat diet, stress, or mild insulin resistance, owing to reduced β cell mass. The possibility of using α 1D -/-mice as a model for type 2 diabetes remains to be examined.
